Serum Soluble ST2 and Diastolic Dysfunction in Hypertensive Patients

Fărcăş, Anca Daniela; Anton, Florin Petru; Goidescu, Cerasela Mihaela; Gavrilă, Iulia Laura; Vida-Simiti, L; Stoia, Mirela Anca

doi:10.1155/2017/2714095

Cited by 25 publications

(26 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Atherosclerosis is currently recognized as an inflammatory disorder [5,6] low-grade inflammation being involved in all stages of atherosclerosis . In recent years, inflammation markers have been recognized as risk factors for cardiovascular disease (CVD) [7][8][9] There are still many unknown facts regarding inflammation in MetS.…”

mentioning

confidence: 99%

The Realtionship Between Inflammation and Metabolic Syndrome (MetS)-A Matter of Gender?

Taut¹,

Orășan²,

Fodor³

et al. 2019

Rev. Chim.

View full text Add to dashboard Cite

Were investigated the relationship between gender, cardiovascular risk factors and inflammation in metabolic syndrome (MetS) patients. 100 consecutive patients (75 women), 73 with MetS, mean age 57.52�9.77 years, were examined. Adhesion molecules (sICAM1, sVCAM1) were measured in the stored serum samples collected using the ELISA method. The classification of MetS was based on IDF guidelines. The study was carried out at the Department of Cardiology, Clinical Rehabilitation Hospital, Cluj-Napoca, Romania. MetS patients presented lower sICAM1 values (225.01�86.75 ng/mL vs 234.22�82.23 ng/mL, p=NS), but higher sVCAM1 values (605.34�298.69 ng/mL vs 552.29�233.77 ng/mL, p=NS). Differences between patients with vs without metabolic syndrome were found only in men for sICAM1 (194.73�37.92 ng/mL vs 282�27.15 ng/mL, p[0.001). Considering the HOMA index, a significant difference for sICAM1 was found in men (patients within the upper quartile vs the lower quartile, p=0.002), but also between women and men within the upper quartile of HOMA (for sICAM1 p=0.038). No significant differences were found for sVCAM1. In the case of males, sICAM1 was an independent predictor of metabolic syndrome, with a very good capacity to identify metabolic syndrome (AUROC=0.987, p=0.0001, Se=89.47%, Sp=100%). In conclusion, just in men, sICAM1 seems to have an excellent capacity to differentiate between MetS+ and MetS- patients, to predict MetS development.

show abstract

mentioning

confidence: 99%

The Realtionship Between Inflammation and Metabolic Syndrome (MetS)-A Matter of Gender?

Taut¹,

Orășan²,

Fodor³

et al. 2019

Rev. Chim.

View full text Add to dashboard Cite

show abstract

“…Our group (Farcas et al) has previously shown that sST2 could be useful as an early diagnostic biomarker for cardiac remodeling and altered diastolic performance in HBP, providing additional data to echocardiography. It could represent a milestone in early detection of cardiac performance alteration [18]. Furthermore, Wang et al performed a larger study on 344 patients with HBP and HFpEF and showed that sST2 measurement provides diagnostic aid of stable HFpEF, correlated with NYHA class and LVDD [19].…”

Section: Discussionmentioning

confidence: 99%

Short-Term Prognosis Value of sST2 for an Unfavorable Outcome in Hypertensive Patients

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background. sST2 represents a useful biomarker for the diagnosis and prognosis of patients with heart failure, but limited data is available on its role in patients with hypertension. The aim of this study is to evaluate the short-term prognosis value of sST2 for an unfavorable outcome in hypertensive patients. Methods. This was a prospective observational study which enrolled 80 patients with hypertension, who were followed for one year. All patients underwent clinical, laboratory (including sST2), and echocardiographic assessment at baseline. The patients were grouped according to the cardiovascular (CV) events reported during the follow-up: group A (with CV events) and group B (without CV events). Results. Overall, 59 CV events were reported during the follow-up period. Compared to group B, the patients in group A had significantly higher sST2 levels, a higher number of CV risk factors, and a higher left ventricle mass. Except for the diastolic dysfunction parameters, the echocardiographic findings were similar in the two groups. Patients in group A had a lower E/A ratio, larger deceleration time, and increased telediastolic pressure as quantified by the E/E′ ratio than those in group B. Multivariate logistic regression analysis showed that sST2 and fasting plasma glucose at baseline were independent predictors for the CV events reported during the follow-up period. sST2 levels > 28:5 ng/mL were associated with poor clinical outcomes (p = 0:006, Kaplan-Meier analysis). Conclusions. sST2 levels were correlated with the risk of adverse CV outcomes in hypertensive patients and may represent a useful prognostic marker in these patients.

show abstract

“…In this context, the circulating level of sST2measured at discharge may improve risk stratification scores based on clinical criteria, SYNTAX score, and other biomarker models [28][29][30] . Previously, an elevated level of sST2 was reported as an independent predictor for survival in patients 2869 with several phenotypes of HF (HFrEF, HFmrEF, HF-pEF), as well as for individuals with STEMI/non-STEMI after PCI and thrombolysis, stable coronary artery diseases, atrial fibrillation, diabetes mellitus [31][32][33][34] . Although there is a wide spectrum of predictive biomarkers in STEMI patients undergoing PCI, sST2 appeared to be superior to NT-proBNP, cardiac troponins, myoglobin, CK-MB and clinical findings in prognostication of early STEMI complications and one-year major adverse cardiovascular and cerebrovascular events, defined as a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and ischemia-driven revascularization 35,36 .…”

Section: Discussionmentioning

confidence: 99%

Elevated levels of circulating soluble ST2 at discharge predict late adverse ventricular remodeling in patients with ST-segment elevation myocardial infarction

2018

View full text Add to dashboard Cite

Introduction: The aim of this study was to investigate whether the circulating level of sST2 would predict adverse LV remodeling in STEMI patients with TIMI III flow through the myocardial infarctrelated coronary artery six months after intervention. Methods: The study retrospectively included 65 patients with STEMI and TIMI-III flow after primary or facilitated percutaneous coronary intervention (PCI). These patients were admitted to the intensive care unit of L.T. Malaya Therapy National Institute between August 2016 and July 2018. Primary PCI with bare-metal stent implantation was performed in 33 patients, and 32 patients were previously treated with primary thrombolysis followed by PCI within 12 hours after initial STEMI confirmation. Angiographic, clinical, and biochemical parameters were evaluated. B-mode, Tissue Doppler, Strain Echocardiography, and blood sampling for biomarker assays were performed at admission, at discharge from the hospital, and at six months after STEMI. Results: Late adverse LV remodeling is defined as an increase of LV end-diastolic volume (EDV) six months post STEMI (first cohort, n=29), while other patients (second cohort, n=36) did not demonstrate a decreasing trend of LV EDV, or they had never revealed any decrease of this parameter. There was a significant difference between the two cohorts in the serum level of sST2 at discharge, while the levels of natriuretic peptides, troponin I were similar (P=0.24). Indeed, the circulating level of sST2 in the first cohort was higher than that of the second cohort (59.72 ng/mL; 95% confidence interval [CI] = 36.99 ng/mL -139.53 ng/mL versus 44.75 ng/mL; 95%CI =28.25 ng/mL -77.32 ng/mL, P=0.039, respectively). ROC-analyses showed that the best balanced cut-off point for sST2 to predict adverse remodeling at 6 months post PCI was 35 ng/mL (AUC=0.672 95% C 0.523-0.799; P=0.0344 sensitivity = 46.7% and specificity = 85.7%). Conclusions: We showed that the circulating level of sST2 measured at discharge in acute STEMI patients intervented by PCI could predict late adverse LV remodeling six months post PCI. These findings offer a new biomarker to stratify patients with successful coronary re-vascularization at risk of HF.

show abstract

Serum Soluble ST2 and Diastolic Dysfunction in Hypertensive Patients

Cited by 25 publications

References 31 publications

The Realtionship Between Inflammation and Metabolic Syndrome (MetS)-A Matter of Gender?

The Realtionship Between Inflammation and Metabolic Syndrome (MetS)-A Matter of Gender?

Short-Term Prognosis Value of sST2 for an Unfavorable Outcome in Hypertensive Patients

Elevated levels of circulating soluble ST2 at discharge predict late adverse ventricular remodeling in patients with ST-segment elevation myocardial infarction

Contact Info

Product

Resources

About